TSC1 regulates the balance between effector and regulatory T cells
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Mammalian target of rapamycin (mTOR) plays a crucial role in the control of T cell fate determination; however, the precise regulatory mechanism of the mTOR pathway is not fully understood. We found that T cell-specific deletion of the gene encoding tuberous sclerosis 1 (TSC1), an upstream negative regulator of mTOR, resulted in augmented Th1 and Th17 differentiation and led to severe intestinal inflammation in a colitis model. Conditional Tsc1 deletion in Tregs impaired their suppressive activity and expression of the Treg marker Foxp3 and resulted in increased IL-17 production under inflammatory conditions. A fate-mapping study revealed that Tsc1-null Tregs that lost Foxp3 expression gained a stronger effector-like phenotype compared with Tsc1-/- Foxp3+ Tregs. Elevated IL-17 production in Tsc1-/- Treg cells was reversed by in vivo knockdown of the mTOR target S6K1. Moreover, IL-17 production was enhanced by Treg-specific double deletion of Tsc1 and Foxo3a. Collectively, these studies suggest that TSC1 acts as an important checkpoint for maintaining immune homeostasis by regulating cell fate determination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
mTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575 · cited 1×
“Recent studies have revealed that the mTOR signaling pathway is crucially involved in the process of T cell fate determination, including the differentiation of naive cells into either effector or regulatory T (Treg) cells and the development of CD8 memory T cells (4–8).”
Koch, M. A., Tucker-Heard, G., Perdue, N. R., Killebrew, J. R., Urdahl, K. B., & Campbell, D. J. (2009) · Nature Immunology · doi:10.1038/ni.1731 · Cited by 1,258
The TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237 · cited 1×
“Genetic deletion of TSC1 or TSC2 causes constitutive activation of mTORC1 signaling, leading to the attenuation of PI3K signaling (12).”
Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., et al. (2011) · Science · doi:10.1126/science.1199498 · Cited by 1,084
Stability of the Regulatory T Cell Lineage in Vivo
Rubtsov, Y. P., Niec, R. E., Josefowicz, S., Li, L., Darce, J., Mathis, D., Benoist, C., & Rudensky, A. Y. (2010) · Science · doi:10.1126/science.1191996 · Cited by 730 · cited 2×
“Treg cell lineage commitment remains controversial (23, 24).”
Cited by
Metabolic coordination of T cell quiescence and activation
Chapman, N. M., Boothby, M. R., & Chi, H. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0203-y · Cited by 751
The regulation of immune tolerance by FOXP3
Lu, L., Barbi, J., & Pan, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.75 · Cited by 580
Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression
Gerriets, V. A., Kishton, R. J., Johnson, M. O., Cohen, S., Siska, P. J., Nichols, A. G., Warmoes, M. O., de Cubas, A. A., MacIver, N. J., Locasale, J. W., et al. (2016) · Nature Immunology · doi:10.1038/ni.3577 · Cited by 539
Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease
DuPage, M., & Bluestone, J. A. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.18 · Cited by 513
Wei, J., Long, L., Yang, K., Guy, C., Shrestha, S., Chen, Z., Wu, C., Vogel, P., Neale, G., Green, D. R., et al. (2016) · Nature Immunology · doi:10.1038/ni.3365 · Cited by 470
Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors
Andrejeva, G., & Rathmell, J. C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.004 · Cited by 373
Metabolic Barriers to T Cell Function in Tumors
Sugiura, A., & Rathmell, J. C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701041 · Cited by 208
mTOR signaling at the crossroads of environmental signals and T‐cell fate decisions
Huang, H., Long, L., Zhou, P., Chapman, N. M., & Chi, H. (2020) · Immunological Reviews · doi:10.1111/imr.12845 · Cited by 193
Chapman, N. M., Zeng, H., Nguyen, T.-L. M., Wang, Y., Vogel, P., Dhungana, Y., Liu, X., Neale, G., Locasale, J. W., & Chi, H. (2018) · Nature Communications · doi:10.1038/s41467-018-04392-5 · Cited by 192
Xie, L., Sun, F., Wang, J., Mao, X., Xie, L., Yang, S.-H., Su, D.-M., Simpkins, J. W., Greenberg, D. A., & Jin, K. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303492 · Cited by 175
mTOR Signaling, Tregs and Immune Modulation
Chapman, N. M., & Chi, H. (2014) · Immunotherapy · doi:10.2217/imt.14.84 · Cited by 148
Intersection of mTOR and STAT signaling in immunity
Saleiro, D., & Platanias, L. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.10.006 · Cited by 142
“Prior evidence suggests that mTOR activity controls the maintenance and function of the CD4+ Treg cell population, which is crucial for the development of immune tolerance [42, 43].”
BackgroundPD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance
van Gulijk, M., van Krimpen, A., Schetters, S., Eterman, M., van Elsas, M., Mankor, J., Klaase, L., de Bruijn, M., van Nimwegen, M., van Tienhoven, T., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abn6173 · Cited by 110
Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy
Munn, D. H., Sharma, M. D., & Johnson, T. S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1351 · Cited by 84
NK cell development requires Tsc1-dependent negative regulation of IL-15-triggered mTORC1 activation
Yang, M., Chen, S., Du, J., He, J., Wang, Y., Li, Z., Liu, G., Peng, W., Zeng, X., Li, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12730 · Cited by 73
Harnessing FOXP3+ regulatory T cells for transplantation tolerance
Waldmann, H., Hilbrands, R., Howie, D., & Cobbold, S. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67226 · Cited by 69
Metadata
- Authors
- Park, Y., Jin, H.-S., Lopez, J., Elly, C., Kim, G., Murai, M., Kronenberg, M., & Liu, Y.-C.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-11-25
- Volume
- 123
- Issue
- 12
- Pages
- 5165-5178
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2093230148
- Cited by
- 143
- References
- 7
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.